SC

Sarath Chandran Sreedharan Nambikeriyil

Director Director DIN 08236118
DIN 08236118 First appointment Sep 2018 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 1 historical roles
Total affiliations 1 Since Sep 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Sarath Chandran Sreedharan Nambikeriyil

Data last updated:

Sarath Chandran Sreedharan Nambikeriyil was a Director at Max Briston Pharmaceutical Private Limited (2018–2021). The company operates in Pharma.

DIN 08236118
Primary Designation Director
Industry Pharma
First Appointment 24 Sep 2018

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Sep 20182015₹5.6 Lakh (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Max Briston Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Sarath Chandran Sreedharan Nambikeriyil

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sarath Chandran Sreedharan Nambikeriyil

Sarath Chandran Sreedharan Nambikeriyil was first appointed on 24 Sep 2018 as Director at Max Briston Pharmaceutical Private Limited.

Sarath Chandran Sreedharan Nambikeriyil held 1 earlier board appointment: Max Briston Pharmaceutical Private Limited (Director, 24 Sep 2018 to 05 Apr 2021).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available